Sight Diagnostics

A group of scientists, engineers, and entrepreneurs launched Sight Diagnostics in 2011. The company's headquarters are in Israel, but it also maintains operations in the United States. The OLO platform has acquired regulatory approval in Europe, the United States, and other countries and is now being utilized in hospitals and clinics worldwide.

Sight Diagnostics is a medical technology firm that has created the OLO AI-powered blood analysis tool. With just two drops of blood, this platform can produce full blood count (CBC) results in minutes. The platform analyzes blood samples using digital microscopy and AI algorithms, offering quick and reliable results that can help clinicians make informed treatment decisions. The technology developed by Sight Diagnostics has the potential to transform the way blood tests are currently performed, making them faster, more accurate, and more accessible to patients.

Sight Diagnostics has created a digital pathology platform called Path in addition to its blood analysis platform. This platform uses AI algorithms to evaluate tissue samples and deliver accurate cancer and other disease diagnosis.

Sight Diagnostics reported sales of around $50.1 million for fiscal year 2023, which is expected to rise substantially in the future. Overall, Sight Diagnostics is dedicated to developing breakthrough technologies that improve the speed and accuracy of medical diagnosis, resulting in better patient outcomes and lower healthcare costs.

Founded: 2011
Headquarters: Jerusalem Technology Park, Jerusalem, Jerusalem, Israel
Website: https://sightdx.com/en-us

Visit website